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ABSTRACT  
   
The apolipoprotein E (APOE) e4 genotype is the most prevalent known genetic 
risk factor for Alzheimer's disease (AD). In this paper, we examined the longitudinal 
effect of APOE e4 on hippocampal morphometry in Alzheimer's Disease Neuroimaging 
Initiative (ADNI). Generally, atrophy of hippocampus has more chance occurs in AD 
patients who carrying the APOE e4 allele than those who are APOE e4 noncarriers. Also, 
brain structure and function depend on APOE genotype not just for Alzheimer's disease 
patients but also in health elderly individuals, so APOE genotyping is considered critical 
in clinical trials of Alzheimer's disease. We used a large sample of elderly participants, 
with the help of a new automated surface registration system based on surface conformal 
parameterization with holomorphic 1-forms and surface fluid registration. In this system, 
we automatically segmented and constructed hippocampal surfaces from MR images at 
many different time points, such as 6 months, 1- and 2-year follow up. Between the two 
different hippocampal surfaces, we did the high-order correspondences, using a novel 
inverse consistent surface fluid registration method. At each time point, using Hotelling's 
T^2 test, we found significant morphological deformation in APOE e4 carriers relative to 
noncarriers in the entire cohort as well as in the non-demented (pooled MCI and control) 
subjects, affecting the left hippocampus more than the right, and this effect was more 
pronounced in e4 homozygotes than heterozygotes. 
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1. INTRODUCTION 
1.1 Medical Background  
 Alzheimer’s disease (AD), a highly prevalent neurodegenerative disease, is 
widely recognized as a major, escalating, epidemic, world-wide challenge to global 
health care systems. AD is the most common type of dementia, accounting for 60-80% of 
age-related dementia cases. The direct cost of care for AD patients by family members or 
healthcare professionals is more than $114 billion per year in US alone; this figure is 
expected to rise dramatically as the population ages during the next several decades (Frey, 
2003). 
 
1.2 Related Work  
 It is commonly agreed that an effective presymptomatic diagnosis and treatment 
of AD would have enormous public health benefits. AD is a neurodegenerative disorder 
characterized by progressive cognitive dysfunction. However, the underlying disease 
pathology most probably precedes the onset of cognitive symptoms by many years. 
Efforts are underway to find early diagnostic markers to evaluate AD risk 
presymptomatically in a sufficiently rapid and rigorous way. The discovery of APOE as 
the most prevalent risk factor for AD (Corder et al., 1993; Saunders et al., 1993) has 
made it possible to study large numbers of genetically at-risk individuals before the onset 
of symptomatic memory impairment and has led to the concept of preclinical stage AD 
(Sperling et al., 2011), a concept validated in autopsy studies of non-demented elderly 
subjects with neuropathological evidence of AD (Bennett et al., 2009; Caselli et al., 2010; 
Dickson et al., 1992; Gouras et al., 1997; Kok et al., 2009), brain imaging studies (Dean 
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et al., 2014; Erten-Lyons et al., 2013; Filippini et al., 2009; Knickmeyer et al., 2014; 
Morris et al., 2010; Reiman et al., 1996; Reiman et al., 2005; Reiman et al., 2009; 
Roussotte et al., 2014a), and neuropsychological studies (Caselli et al., 2011; Caselli et 
al., 2009). As the paradigm in AD research shifts to a new stage, targeting earlier 
intervention and prevention, APOE genotyping is currently considered beneficial in 
prevention trials for AD because the selective enrollment of APOE e4 carriers may 
accelerate the evaluation of preclinical or presymptomatic AD treatments (Caselli and 
Reiman, 2013; Langbaum et al., 2013). 
 Brain imaging and cerebrospinal fluid (CSF) biomarkers may help in the 
preclinical detection, tracking and scientific of AD. Structural magnetic resonance 
imaging (MRI) measurements of regional and whole brain tissue shrinkage, together with 
fluorodeoxyglucose positron emission tomography (FDG PET) measurements of decline 
in the regional cerebral metabolic rate for glucose (CMRgl), and PET measurements of 
fibrillar amyloid-β (Aβ) burden are among the best established measurement for the 
preclinical detection and tracking of AD (Reiman and Jagust, 2012). In AD research, 
structural magnetic resonance imaging (MRI) based measures include whole-brain (Chen 
et al., 2007; Fox et al., 1999; Stonnington et al., 2010), entorhinal cortex (Cardenas et al., 
2009), hippocampus (den Heijer et al., 2010; Jack et al., 2003; Reiman et al., 1998; Shi et 
al., 2014; Thompson et al., 2004; Wolz et al., 2010), and temporal lobe volumes (Hua et 
al., 2010), as well as ventricular enlargement (Jack et al., 2003; Shi et al., 2015; 
Thompson et al., 2004; Wang et al., 2011). Since reductions in hippocampal and 
entorhinal cortex volumes become apparent in the early stages of memory decline and 
may anticipate progression to MCI and AD (de Leon et al., 1989; Jack et al., 2004), 
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hippocampal atrophy measures with structural MRI were one of the most studied brain 
imaging biomarkers for early detection and tracking of AD. It is natural for us to develop 
novel imaging measure of hippocampal morphometry which discovers the association 
between APOE genotype and the structural MRI patterns of hippocampal deformation 
and benefits preclinical AD research. 
 
1.3 Thesis Overview 
 In our recent work (Shi et al., 2014), we automatically segmented and constructed 
hippocampal surfaces from the baseline MR images of 725 subjects with known APOE 
genotype information including 167 with AD, 354 with mild cognitive impairment (MCI), 
and 204 normal controls. We also build high-order correspondences between 
hippocampal surfaces and compute multivariate statistics consisting multivariate tensor-
based morphometry (mTBM) and radial distance. Using Hotelling’s T2 test, we found 
significant morphological deformation in APOE e4 carriers relative to non-carriers in the 
entire cohort as well as in the non-demented (pooled MCI and control) subjects, affecting 
the left hippocampus more than the right, and this effect was more pronounced in e4 
homozygotes than heterozygotes. In this paper, we extend our prior work (Shi et al., 2014) 
to study a large dataset of brain MR images (N=1925) from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI). To track the longitudinal hippocampal atrophy across 
baseline, 6-month (N=724), 12-month (N=673) and 24-month (N=533) follow up scans, 
we applied a novel surface multivariate tensor-based morphometry (mTBM) system (Shi 
et al., 2013a; Shi et al., 2013q; Wang et al., 2012; Wang et al., 2011; Wang et al., 2010) 
to create 3D maps of hippocampal atrophy associated with the APOE e4 genotype. We 
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hypnotized that (1) we may observe the similar patterns on different time points, 6-
months, 12-months and 24-months, as what we observed in the baseline study (Shi et al., 
2014); (2) the degree of hippocampal deformation would relate to genetic risk groups for 
AD, particularly, the APOE e4 homozygotes may have a faster longitudinal hippocampal 




















2. SUBJECTS AND METHODS 
2.1 Subjects  
 Data used in the preparation of this thesis were obtained from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was 
launched in 2003 by the National Institute on Aging (NIA), the National Institute of 
Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration 
(FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 
5-year public-private partnership. The primary goal of ADNI has been test whether serial 
magneticreasonance imaging (MRI), positron emission tomography (PET), other 
biological markers, and clinical and neuropsychological assessment can be combined to 
measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s 
disease (AD). Determination of sensitive and specific markers of very early AD 
progression is intended to aid researchers and clinicians to develop new treatments and 
monitor their effectiveness, as well as lessen the time and cost of clinical trials. 
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA 
Medical Center and University of California – San Francisco. ADNI is the result of 
efforts of many co-investigators from a broad range of academic institutions and private 
corporations, and subjects have been recruited from over 50 sites across the U.S. and 
Canada. The initial goal of ADNI was to recruit 800 subjects but ADNI has been 
followed by ADNI-GO and ADNI-2. To date these three protocols have recruited over 
1500 adults, ages 55 to 90, to participate in the research, consisting of cognitively normal 
older individuals, people with early or late MCI, and people with early AD. The follow 
up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and 
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ADNIGO. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be 
followed in ADNI-2. For up-to-date information, see www.adni-info.org. 
At the time of downloading (September 2011), the baseline dataset consisted of 
843 adults, ages 55 to 90, including 233 elderly healthy controls (CTL), 410 subjects with 
mild cognitive impairment (MCI) and 200 AD patients. The 6 month dataset consisted of 
adults, ages 55 to 90, including 214 elderly healthy controls (CTL), 359 subjects with 
mild cognitive impairment (MCI) and 165 AD patients. The 12 month dataset consisted 
of adults, ages 55 to 90, including 203 elderly healthy controls (CTL), 338 subjects with 
mild cognitive impairment (MCI) and 144 AD patients. The 24 month dataset consisted 
of adults, ages 55 to 90, including 178 elderly healthy controls (CTL), 254 subjects with 
mild cognitive impairment (MCI) and 111 AD patients. All subjects underwent thorough 
clinical and cognitive assessment at the time of acquisition, including the Mini-Mental 
State Examination (Folstein et al., 1975), Clinical Dementia Rating (CDR) (Berg, 1988), 
and Delayed Logical Memory Test (Wechsler, 1987). APOE genotyping was performed 
on DNA samples obtained from subjects’ blood, using an APOE genotyping kit, as 
described in http://www.adni-info.org for detailed information on blood sample 
collection, DNA preparation, and genotyping methods. 
Participants were scanned with a standardized MRI protocol developed for this 
cohort (Jack et al., 2008). We applied our hippocampal morphometry pipeline (Shi et al., 
2014; Shi et al., 2013a) to reconstruct hippocampal meshes (detailed in Sec. 2.3). As a 
quality control, we manually checked all the constructed meshes. In 6-months data, we 
manually excluded 3 subjects from CTL group , 6 subjects from MCI group and 5 
subjects from AD group with wrong surface topologies (Shi et al., 2014; Shi et al., 
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2013a). Similarly, in 12-months data, we manually excluded 3 subjects from CTL group, 
8 subjects from MCI group, and 1 subject from AD group. In 24-months data, we 
manually excluded 2 subjects from CTL group, 5 subjects from MCI group, and 3 
subjects from AD group. As a result, a total of 1925 ADNI longitudinal brain MR scans, 
including 211 controls (mean age is 76.41), 353 MCI (mean age is 75.06), and 160 AD 
(mean age is 74.88) from the 6-months data, 200 controls (mean age is 76.38), 330 MCI 
(mean age is 74.82), and 143 AD (mean age is 75.63) from the 12-months data, 176 
controls (mean age is 76.44), 249 MCI (mean age is 74.75), and 108 AD (mean age is 
75.17) from the 24-months data, were analyzed in the study. We also used their baseline 
data as a reference to study the longitudinal effects. The baseline data information and 
processing results were reported in our prior work (Shi et al., 2014). Table 1 gives 















CON MCI AD Total 
0 APOE e4 
allele 
    
N6 115(52) 127(44) 43(21) 285(117) 
N12 104(46) 120(41) 40(18) 264(105) 
N24 98(46) 90(33) 28(13) 216(92) 
Age 76.51(±4.91) 76.13(±7.53) 76.82(±8.55) 76.39(±6.75) 
MMSE 29.10(±1.13) 26.54(±3.36) 20.79(±5.00) 26.77(±4.06) 
1 APOE e4 
allele 
    
N6 43(21) 125(44) 61(25) 229(90) 
N12 44(21) 117(41) 58(25) 219(87) 
N24 40(19) 86(26) 45(18) 171(63) 
Age 76.43(±4.42) 74.67(±6.65) 75.70(±6.06) 75.30(±6.13) 
MMSE 28.79(±2.92) 25.41(±3.59) 21.25(±4.66) 24.96(±4.69) 
2 APOE e4 
allele 
    
N6 3(1) 41(18) 32(13) 76(32) 
N12 4(2) 39(16) 28(10) 71(28) 
N24 4(2) 31(12) 21(9) 56(23) 
Age 73.36(±2.92) 71.82(±5.74) 72.07(±6.91) 72.00(±6.13) 
MMSE 29.09(±1.58) 25.68(±3.31) 20.72(±5.23) 23.88(±4.92) 
Total     
N6 161(74) 293(106) 136(59) 590(239) 
N12 152(69) 276(98) 126(53) 554(220) 
N24 142(67) 207(71) 94(40) 443(178) 
Age 76.41(±4.76) 74.89(±7.07) 75.22(±7.31) 75.40(±6.58) 
MMSE 29.01(±1.82) 25.94(±3.49) 20.99(±4.89) 25.71(±4.52) 
Table 1. Demographic data by diagnositic and genotype groups. 
In Table 1, N6, N12, and N24 indicate sample size at 6-month, 12-month and 24-
month follow up cohorts, respectively. The number of women in the sample sizes are 
indicated in parentheses. Means are followed by standard deviations in parentheses for 
age and MMSE measures.  
In our study, following prior work (Morra et al., 2009a; Morra et al., 2009c; Shi et 
al., 2014; Shi et al., 2013a), we pooled both the subjects who are heterozygotes APOE e4 
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carriers (e3/e4) and homozygotes APOE e4 carriers (e4/e4) together to form the APOE e4 
carriers group and correlated presence of the APOE e4 allele with hippocampal 
morphometry, both (1) in the entire sample and (2) in non-demented (pooled MCI and 
controls) subjects. Throughout the paper, we call these two populations as the full ADNI 
cohort and non-demented cohort, respectively.  
 
2.2 Processing Pipeline 
 Figure 1 summarizes the overall processing sequence. The original input data 
were the three-dimensional (3D) T1-weighted images from ADNI dataset (6-months, 12-
months and 24-months), an example image is shown in Figure 1 (a). First, we used the 
FIRST (FMRIB’s Integrated Registration and Segmentation Tool) software (Patenaude et 
al., 2011) to segment the original data and got the hippocampus substructure. The 
hippocampal surfaces were automatically reconstructed based on binary segmentation 
results (Shi et al., 2014; Shi et al., 2013a). Second, we generated a conformal grid for 
each surface with the holomorphic 1-form based on the surface conformal 
parameterization (Wang et al., 2011). With the help of conformal grid, we can compute 
the conformal factor (intrinsic features of the surface) and mean curvature (extrinsic 
features of the surface), which are the conformal representation of the surface (Shi et al., 
2014; Shi et al., 2013a). And then, we can take advantage of conformal factor and mean 
curvature to compute the “feature image” of a surface. Thirdly, registering the feature 
image of each surface in the dataset to a common template with an inverse consistent 
fluid registration algorithm. With conformal parameterization, the 3D surface registration 
problem was converted into a 2D image registration problem. The flow induced in the 
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parameter domain establishes high-order correspondences between 3D surfaces. Finally, 
we studied the longitudinal differences between different diagnostic groups with the 
multivariate tensor-based morphometry (mTBM) statistics (Wang et al., 2010) which 
retain the full tensor information of the deformation Jacobian matrix, together with the 
radial distance, which retains information on the deformation along the surface normal 
direction. The similar processing pipeline was used in several of our prior work (Joshi et 




 Figure 1. Overall processing sequence 
 In Figure 1, (a): Longitudinal data (6-months, 12-months and 24-months) were 
obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database; (b) 
automatic hippocampus segmentation with FIRST software (Patenaude et al., 2011); (c) 
hippocampal surface reconstruction with marching cube method (Lorensen and Cline, 
1987); (d) hippocampal surface conformal parameterization with holomorphic 1-forms 
(Wang et al., 2007c); (e) groupwise inverse consistent surface fluid registration of 
hippocampal surfaces (Shi et al., 2013a); (f) multivariate statistics (Wang et al., 2010) 
consisting of radial distance and multivariate TBM; (g) longitudinal genetic influence of 
APOE e4 allele on hippocampal morphometry. 
 
2.3 Hippocampus Segmentation and Surface Modeling 
 In the process of segmentation, we used FIRST (Patenaude et al., 2011) to 
automatically all T1-weighted MR images. FIRST is a model based subcortical structure 
segmentation and registration tool developed as part of the FSL library, which is written 
mainly by members of the Analysis Group, FMRIB, Oxford, UK. The shape/appearance 
models used in FIRST are constructed from manually segmented images provided by the 
Center for Morphometric Analysis (CMA), MGH, Boston. With the FIRST, we ran the 
run_first_all routine with default parameters tuned by FIRST as optimal for hippocampal 
segmentation. For now, we took three-phase image which contains the labels of the left 
and right hippocampi. The binary image of each side of hippocampus was obtained by a 
simple thresholding process. Figure 1 (b) shows an example of segmented hippocampus 
substructure. Then hippocampal surfaces were constructed with a topology-preserving 
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level set method (Han et al., 2003), which is based on the binary segmentations, and we 
can obtain the triangular surface meshes by using the marching cubes algorithm 
(Lorensen and Cline, 1987). After mesh refinement (Shi et al., 2014; Shi et al., 2013a), 
we obtained smooth surfaces that are suitable for generating conformal grids. Finally, 
with the help of global affine transformation with a nine-parameter (three parameters for 
translation, three parameters for rotation, and three parameters for scaling) matrix that 
was computed by FIRST, the smoothed meshes were aligned into the MNI standard space. 
Figure 1 (c) shows a pair of reconstructed hippocampal surfaces. 
 
2.4 Conformal Grid Generation and Conformal Representation 
 To facilitate hippocampal shape analysis, we generated a conformal grid on each 
surface, which is used as a canonical space for surface registration and multivariate 
statistical analysis. We applied an automatic topological optimization algorithm to 
introduce two cuts on each hippocampal surface to convert it into a genus zero surface 
with two open boundaries (Shi et al., 2014; Shi et al., 2013a). The locations of the two 
cuts are at the front and back of the hippocampal surface, representing its anterior 
junction with the amygdala, and its posterior limit as it turns into the white matter of the 
fornix. They are biologically valid and consistent landmarks across subjects. Given the 
hippocampal tube-like shape, these landmark curves are automatically determined by 
checking the extreme points when searching along the first principle direction of 
geometric moments of surface (Elad et al., 2004; Wang et al., 2011; Zhang and Lu, 2004). 
For quality control purposes, we have manually checked the consistency of all landmark 
curves. On each hippocampal surface, we compute harmonic 1-form basis which is the 
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union of the exact 1-form basis and closed but non-exact 1 form basis (Wang et al., 2007c; 
Wang et al., 2010). By solving a linear system with the harmonic 1-form basis, we 
obtained the conjugate of the exact 1-form basis. The exact 1-form basis and its conjugate 
1-form form the holomorphic 1-form basis, which induces a conformal grid on the 
hippocampal surface. Figure 1 (d) shows an example hippocampal surface with its exact 
1-form basis, conjugate 1-form basis and holomorphic 1-form basis and its rectangular 
parameter domain. In the picture, the overlaid texture is used to demonstrate the 
computed 1-form bases. The checkboard texture is used to show the angle preserving 
property, i.e. the right angles on the planar checkerboard texture are well preserved after 
they are overlaid on hippocampal surfaces.    
We adopted surface conformal representation (Shi et al., 2014; Shi et al., 2013a) 
as surface geometric features for automated surface registration. It is consisted of 
conformal factor and mean curvature, encoding both intrinsic surface structure and 3D 
embedding information. Specifically, the conformal factor describes the intrinsic surface 
features while the mean curvature describes the extrinsic features. They uniquely 
determine a 3D closed surface up to a rigid motion. Both measurements, the conformal 
factor and mean curvature, are local features which are defined on each surface vertex. 
The conformal factor is the area ratio of an infinitesimal region around a point on the 
surface and an infinitesimal region around the same point on the planar parameter domain. 
The mean curvature is the average of the two principle curvatures defined on each surface 
point. After we computed these two local features on each surface point, we computed 
their summation and then linearly scaled the dynamic range of the summation into [0, 
255] to get the feature image of the surface.  
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2.5 Hippocampal Surface Registration  
In order to do the longitudinal morphometric analysis, we need to register each 
individual hippocampal surface to a common template surface. With surface conformal 
parameterization and conformal representation, we converted the 3D surface registration 
problem into a 2D image registration problem. The well-studied image fluid registration 
algorithm (Bro-Nielsen and Gramkow, 1996; D'Agostino et al., 2003) can be easily 
applied to induce a deformation flow in the parameter domain, which in turn enforces a 
high-order correspondence in 3D. In order to compensate for the parameterization area 
distortion, we introduced a correction term in the traditional Navier–Stokes equation. 
With conformal parameterization, the correction term was simply the conformal factor 
and the surface fluid registration can be easily developed by extending the Navier–Stokes 
equation to drive flows on general surfaces, regardless of the underlying 
parameterizations. This method is called surface fluid registration (Shi et al., 2013a). 
Furthermore, most image registration algorithms in the literature are not 
symmetric, i.e., the correspondences established between the two images depend on 
which image is assigned as the deforming image and which is the non-deforming target 
image. An asymmetric algorithm can be problematic as they tend to penalize the 
expansion of image regions more than shrinkage (Rey et al., 2002). Thus, in our system, 
we further extended the surface fluid registration method into an inverse consistent 
framework (Leow et al., 2005). The obtained surface registration is diffeomorphic. For 




2.6 Surface Multivariate Morphometry Statistics 
Our multivariate morphometry statistical analysis consists of multivariate tensor-
based morphometry (mTBM)  (Shi et al., 2014; Shi et al., 2013a; Wang et al., 2011; 
Wang et al., 2010) and radial distance analysis (Pizer et al., 1999; Thompson et al., 2004). 
This combines complementary information from mTBM, which measures deformation 
within surfaces, and radial distance, which measures hippocampal size in terms of the 
surface normal direction. 
The mTBM statistics have been carefully studied in brain structure morphology 
analyses and they can demonstrate improved signal detection power relative to more 
standard Jacobian matrix statistics (Shi et al., 2013a; Shi et al., 2013q; Wang et al., 2012; 
Wang et al., 2011; Wang et al., 2013). As mTBM retains the full information in the 
deformation tensor fields, it is very sensitive to deformations such as rotation, dilation, 
and shear along the surface tangent direction, which is perpendicular to the surface 
normal. Given the hippocampal tube-like shape, its atrophy and enlargement directly 
affect the distance from each surface point to its medial core (analogous to the center line 
in a tube). We call this distance the radial distance of a hippocampal surface. Radial 
distance mainly describes morphometric changes along the surface normal direction and 
has been applied in many subcortical studies (Bansal et al., 2000; Gerig et al., 2001; 
Morra et al., 2009c; Pizer et al., 1999; Thompson et al., 2004). Thus, these two statistics 
are complementary to each other. In this paper, we adopted the multivariate statistics 
proposed in (Wang et al., 2011) to study shape differences between groups with different 
diagnosis, APOE e4 dose, and healthy controls. 
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As in our prior work (Wang et al., 2011), the mTBM was computed as a 3×1 
vector consisting of the “Log-Euclidean metric” (Arsigny et al., 2006), computed as the 
matrix logarithm of the deformation tensor. Given a hippocampal surface with the 
conformal parameterization as described in Sec. 2.4, the radial distance was computed as 
the distance from each parametric surface point to the center of 3D positions of the iso-u 
curves in the parameter domain (Wang et al., 2011), as shown by the red curves in 
Figure 1 (f). We formed the new multivariate surface morphometry statistic as a 4×1 
vector consisting of the mTBM and radial distance.  
 
2.7 Statistical Group Difference 
 To assess group differences with multivariate statistics, we applied Hotelling's 2T  
test (Cao and Worsley, 1999; Hotelling, 1931; Kim et al., 2012b; Thirion et al., 2000) on 
sets of values in the log-Euclidean space of the deformation tensors. For each surface 
vertex, given two groups of 4×n -dimensional vectors, 𝑆! , 𝑖 = 1,2,… ,𝑝,𝑇! , 𝑗 = 1,2,… , 𝑞, 
we used the Mahalanobis distance 𝑀 to measure the group mean difference, 
𝑀 = !!!!!!!!! 𝑆 − 𝑇 !∑!! 𝑆 − 𝑇 .                                                       
where 𝑁! and 𝑁! are the numbers of subjects in the two groups,  𝑆 and 𝑇 are the means of 
the two groups and ∑ is the combined covariance matrix of the two groups (Leporé et al., 
2008; Wang et al., 2011; Wang et al., 2010).  
Specifically, for each hippocampal surface point, we ran a permutation test with 
10,000 random assignments of subjects to different groups to estimate the statistical 
significance of the areas with group difference in surface morphometry. We also used a 
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pre-defined statistical threshold of 𝑝 = 0.05 at each surface point to estimate the overall 
significance of the group difference maps by non-parametric permutation testing (Holmes 
et al., 1996; Nichols and Holmes, 2002). In each case, the covariate (group membership) 
was permuted 10,000 times and a null distribution was developed for the area of the 
average surface with group difference statistics above the pre-defined threshold in the 
significance map. The overall significance of the map is defined as the probability of 
finding, by chance alone, a statistical map with at least as large a surface area beating the 
pre-defined statistical threshold of 𝑝 = 0.05. This omnibus p-value is commonly referred 
to as the overall significance of the map (or the features in the map), corrected for 
multiple comparisons. It basically quantifies the level of surprise in seeing a map with 
this amount of the surface exceeding a pre-defined threshold, under the null hypothesis of 
no systematic group differences. The permutation test on the overall rejection areas is 
used to evaluate the significance of overall experimental results and correct the overall 
significant p-values for multiple comparisons. Figure 1 (g) shows an example of the 
significance p-map with uncorrected p-values, which is used to visualize the surface 










 Similar to our prior work (Shi et al., 2014), we mainly focused on studying the 
effects of APOE e4 genotype on hippocampal morphometry in two populations: (1). the 
full ADNI cohort; (2) the non-demented cohort, i.e., patients of MCI and normal control 
subjects. Subjects with one e2 allele, i.e., e2/e3 and e2/e4 were excluded due to the 
possible protective effect of e2 allele for AD (Morra et al., 2009c; Shi et al., 2014). To 
explore whether APOE e4 allele dose affects hippocampal surface morphometry and how 
this atrophy is related to normal aging, we studied hippocampal morphometry between 
persons homozygotes for the APOE e4 allele and those heterozygotes for this allele. We 
studied group differences between heterozygotes and homozygotes APOE e4 subjects in 
the full ADNI cohort, and in the nondemented APOE e4 carrier cohort in ADNI 6-month, 
12-month and 24-month follow up datasets. The experiments aimed to determine if the 
APOE e4 allele was associated with hippocampal atrophy in all subjects or in subjects 
who have not yet developed AD. 
 
3.1 Results on the Full ADNI Cohort 
3.1.1 Effects of APOE e4 genotype 
 To explore whether the presence of the APOE e4 allele was associated with 
greater hippocampal atrophy, we study the effects of APOE e4 genotype in three follow 
up cohorts. In the 6-month follow up, there were 285 non-carriers (all homozygotes for 
APOE e3, e3/e3) and 305 APOE e4 carriers (e3/e4 and e4/e4). In the 12-month follow up, 
there were 265 non-carriers (e3/e3) and 290 APOE e4 carriers (e3/e4 and e4/e4). In the 
24-month follow up, there were 218 non-carriers (e3/e3) and 226 APOE e4 carriers 
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(e3/e4 and e4/e4). Figure 2 shows the statistical p-maps for these 3 different follow up 
time points, specifically, (a) for 6-month follow up (N=590, 285 non-carriers vs. 305 
carriers), (b) for 12-month follow up (N=555, 265 non-carriers vs. 290 carriers), and (c) 
for 24-month follow up (N=444, 218 non-carriers vs. 226 carriers). Non-blue colours 
show vertices with statistical differences at the nominal 0.05 level, uncorrected for 
multiple comparisons. After correcting for multiple comparisons, the differences 
remained highly significant (p<0.0001 for 6-month, p<0.0001 for 12-month, p<0.0005 
for 24-month). 
 
Figure 2. Illustration of local shape differences (P values) between the APOE e4 
noncarriers (e3/e3) and carriers (e3/e4 and e4/e4) in the full ADNI cohort. 
3.1.2 APOE e4 dose effects: group difference between APOE e4 homozygotes and 
APOE e4 heterozygotes 
 To explore whether APOE e4 allele dose affects hippocampal surface 
morphometry and how this atrophy is related to normal aging, we studied hippocampal 
morphometry between persons homozygotes for the APOE e4 allele and those 
heterozygotes for this allele in three follow up cohorts. In the 6-month follow up cohort, 
76 subjects were homozygotes (e4/e4) and 229 were heterozygotes (e3/e4) for APOE e4 
allele. In the 12-month follow up cohort, 71 subjects were homozygotes (e4/e4) and 219 
were heterozygotes (e3/e4) for APOE e4 allele. In the 24-month follow up cohort, 56 
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subjects were homozygotes (e4/e4) and 170 were heterozygotes (e3/e4) for APOE e4 
allele. Figure 3 shows the statistical p-maps for these 3 different follow up time points, 
specifically, (a) for 6-month follow up (N=305, 76 e4 homozygotes vs. 229 e4 
heterozygotes), (b) for 12-month follow up (N=290, 71 e4 homozygotes vs. 219 
heterozygotes), and (c) for 24-month follow up (N=226, 56 e4 homozygotes vs. 170 
heterozygotes). Non-blue colours show vertices with statistical differences at the nominal 
0.05 level, uncorrected for multiple comparisons. After correcting for multiple 
comparisons, the differences remained significant for the 6- and 12-month cohort but not 
for the 24-month cohort. (p<0.0117 for 6-month, p<0.0024 for 12-month, p<0.0959 for 
24-month). 
 
Figure 3. Illustration of local shape differences (P values) between the heterozygotes 
APOE e4 carriers (e3/e4) and the homozygotes APOE e4 carriers (e4/e4) in the full 
ADNI cohort. 
3.1.3 APOE e4 dose effects: group difference between APOE e4 homozygotes and 
APOE e4 non-carriers 
 We also studied hippocampal morphometry between persons homozygotes for the 
APOE e4 allele and the APOE e4 non-carriers. In the 6-month follow up cohort, there 
were 76 e4 homozygotes (e4/e4) and 285 e4 non-carriers (all homozygotes for APOE e3, 
e3/e3). In the 12-month follow up cohort, there were 71 homozygotes (e4/e4) and 265 
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noncarriers (e3/e3). In the 24-month follow up cohort, there were 56 homozygotes (e4/e4) 
and 218 noncarriers (e3/e3). Figure 4 shows the statistical p-maps for these 3 different 
follow up time points, specifically, (a) for 6-month follow up (N=361, 76 e4 
homozygotes vs. 285 non-carriers), (b) for 12-month follow up (N=336, 71 e4 
homozygotes vs. 265 non-carriers), and (c) for 24-month follow up (N=274, 56 e4 
homozygotes vs. 170 non-carriers). Non-blue colours show vertices with statistical 
differences at the nominal 0.05 levels, uncorrected for multiple comparisons. After 
correcting for multiple comparisons, the differences remained significant for all three 
cohorts. (p<0.0001 for 6-month, p<0.0001 for 12-month, p<0.0001 for 24-month).  
 
Figure 4. Illustration of local shape differences (P values) between the APOE e4 
noncarriers (e3/e3) and the homozygotes APOE e4 carriers (e4/e4) in the full ADNI 
cohort. 
3.1.4 APOE e4 dose effects: group difference between APOE e4 heterozygotes and 
APOE e4 non-carriers 
 We further studied hippocampal morphometry between persons heterozygotes for 
the APOE e4 allele and the APOE e4 non-carriers. In the 6-month follow up cohort, there 
were 229 APOE e4 heterozygotes (e3/e4) and 285 e4 non-carriers (all homozygotes for 
APOE e3, e3/e3). In the 12-month follow up cohort, there were 219 heterozygotes (e3/e4) 
and 265 non-carriers (e3/e3). In the 24-month follow up cohort, there were 170 
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heterozygotes (e3/e4) and 218 non-carriers (e3/e3). Figure 5 shows the statistical p-maps 
for these 3 different follow up time points, specifically, (a) for 6-month follow up 
(N=514, 229 e4 heterozygotes vs. 285 non-carriers), (b) for 12-month follow up (N=484, 
219 e4 heterozygotes vs. 265 non-carriers), and (c) for 24-month follow up (N=388, 170 
e4 heterozygotes vs. 218 non-carriers). Non-blue colours show vertices with statistical 
differences at the nominal 0.05 level, uncorrected for multiple comparisons. After 
correcting for multiple comparisons, the differences remained significant for all three 
cohorts. (p<0.0116 for 6-month, p<0.0039 for 12-month, p<0.0003 for 24-month). 
 
Figure 5. Illustration of local shape differences (P values) between the APOE e4 
noncarriers (e3/e3) and the heterozygotes APOE e4 carriers (e3/e4) in the full ADNI 
cohort. 
 
3.2 Results on the Non-demented ADNI Cohort 
3.2.1 Effects of APOE e4 genotype 
 In the 6-month follow up non-demented cohort, there were 242 APOE e4 non-
carriers (all homozygotes for APOE e3, e3/e3) and 212 e4 carriers (e3/e4 and e4/e4). In 
the 12-month follow up non-demented cohort, there were 225 non-carriers (e3/e3) and 
204 e4 carriers (e3/e4 and e4/e4). In the 24-month follow up non-demented cohort, there 
190 noncarriers (e3/e3) and 160 e4 carriers (e3/e4 and e4/e4). Figure 6 shows the 
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statistical p-maps for these 3 different follow up time points, specifically, (a) for 6-month 
follow up (N=454, 242 non-carriers vs. 212 e4 carriers), (b) for 12-month follow up 
(N=429, 225 non-carriers vs. 204  e4 carriers), and (c) for 24-month follow up (N=350, 
190 non-carriers vs. 160 e4 carriers). Non-blue colours show vertices with statistical 
differences at the nominal 0.05 level, uncorrected for multiple comparisons. After 
correcting for multiple comparisons, the differences remained significant for all three 
cohorts. (p<0.0010 for 6-month, p<0.0005 for 12-month, p<0.0015 for 24-month). 
 
Figure 6. Illustration of local shape differences (P values) between the APOE e4 
noncarriers (e3/e3) and carriers (e3/e4 and e4/e4) in the nondemented cohort. 
3.2.2 APOE e4 dose effects: group difference between APOE e4 homozygotes and 
APOE e4 heterozygotes 
 In the 6-month follow up non-demented cohort, there were 44 homozygotes 
(e4/e4) and 168 e4 heterozygotes (e3/e4). In the 12-month follow up non-demented 
cohort, there were 43 homozygotes (e4/e4) and 161 e4 heterozygotes (e3/e4). In the 24-
month follow up non-demented cohort, there were 35 homozygotes (e4/e4) and 125 e4 
heterozygotes (e3/e4). Figure 7 shows the statistical p-maps for these 3 different follow 
up time points, specifically, (a) for 6-month follow up (N=212, 44 homozygotes vs. 168 
heterozygotes), (b) for 12-month follow up (N=204, 43 homozygotes vs. 161  
heterozygotes), and (c) for 24-month follow up (N=160, 35 homozygotes vs. 125 
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heterozygotes). Non-blue colours show vertices with statistical differences at the nominal 
0.05 level, uncorrected for multiple comparisons. After correcting for multiple 
comparisons, the differences only remained significant for 12-month cohort (p<0.0204) 
and not for the other two cohorts (p<0.1351 for 6-month, p<0.1870 for 24-month). 
 
Figure 7. Illustration of local shape differences (P values) between the heterozygotes 
APOE e4 carriers (e3/e4) and the homozygotes APOE e4 carriers (e4/e4) in the 
nondemented cohort. 
3.2.3 APOE e4 dose effects: group difference between APOE e4 homozygotes and 
APOE e4 non-carriers 
 In the 6-month follow up non-demented cohort, there were 44 e4 homozygotes 
(e4/e4) and 242 e4 non-carriers (all homozygotes for APOE e3, e3/e3). In the 12-month 
follow up non-demented cohort, there were 43 homozygotes (e4/e4) and 225 e4 non-
carriers (e3/e3). In the 24-month follow up non-demented cohort, there were 35 
homozygotes (e4/e4) and 190 e4 non-carriers (e3/e3). Figure 8 shows the statistical p-
maps for these 3 different follow up time points, specifically, (a) for 6-month follow up 
(N=286, 44 homozygotes vs. 242 non-carriers), (b) for 12-month follow up (N=268, 43 
homozygotes vs. 225 non-carriers), and (c) for 24-month follow up (N=225, 35 
homozygotes vs. 190 non-carriers). Non-blue colours show vertices with statistical 
differences at the nominal 0.05 level, uncorrected for multiple comparisons. After 
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correcting for multiple comparisons, the differences remained significant for 6- and 12-
month cohorts (p<0.0035 for 6-month and p<0.0010 for 12-month) but not for 24-moth 
cohorts (p<0.0770 for 24-month). 
 
Figure 8. Illustration of local shape differences (P values) between the APOE e4 
noncarriers (e3/e3) and the homozygotes APOE e4 carriers (e4/e4) in the nondemented 
cohort. 
3.2.4 APOE e4 dose effects: group difference between APOE e4 heterozygotes and 
APOE e4 non-carriers 
 In the 6-month follow up non-demented cohort, there were 168 e4 heterozygotes 
(e3/e4) and 242 e4 non-carriers (all homozygotes for APOE e3, e3/e3). In the 12-month 
follow up non-demented cohort, there were 161 e4 heterozygotes (e3/e4) and 225 e4 non-
carriers (e3/e3). In the 24-month follow up non-demented cohort, there were 125 
heterozygotes (e3/e4) and 190 e4 non-carriers (e3/e3). Figure 9 shows the statistical p-
maps for these 3 different follow up time points, specifically, (a) for 6-month follow up 
(N=410, 168 heterozygotes vs. 242 non-carriers), (b) for 12-month follow up (N=386, 
161 homozygotes vs. 225 non-carriers), and (c) for 24-month follow up (N=315, 125 
heterozygotes vs. 190 non-carriers). Non-blue colours show vertices with statistical 
differences at the nominal 0.05 level, uncorrected for multiple comparisons. After 
correcting for multiple comparisons, the differences remained significant for 6- and 24-
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month cohorts (p<0.0058 for 6-month and p<0.0110 for 24-month) but not for 12-moth 
cohorts (p<0.1191 for 12-month). 
 
Figure 9. Illustration of local shape differences (P values) between the APOE e4 
noncarriers (e3/e3) and the heterozygotes APOE e4 carriers (e3/e4) in the nondemented 
cohort.  
 
3.3 Results on the Arizona APOE Cohort 
 Besides the ADNI data, we also used the longitudinal volumetric MRI data from a 
subset of health study participants with 0, 1 or 2 copies of APOE e4 alleles, obtained at 
the BAI (Banner Alzheimer’s Institute).  
 This BAI dataset includes two scan cohorts: subjects had their follow up scans 
two years after their baseline ones. Subjects with one e2 allele, i.e., e2/e3 and e2/e4, are 
excluded from our study due to the possible protective effect of e2 allele for AD. As a 
result, the baseline scan cohort had data from 152 subjects, including 57 non-carriers of 
e4 (e3/e3, mean age is 57.47), 45 heterozygous subjects (e3/e4, mean age is 56.51) and 
33 homozygous subjects (e4/e4, mean age is 56.51). The follow up scan cohort had data 
from 123 subjects, including 43 non-carriers of e4 (e3/e3, mean age is 57.47), 38 
heterozygous subjects (e3/e4, mean age is 56.86) and 27 homozygous subjects (e4/e4, 
mean age is 56.02). 
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 In both first and second cohorts, we found no cognitive performance differences 
among the 3 groups.  We also did not find any significant differences between groups in 
the first scan cohort. Figure 10 shows the statistical p-maps for these 3 different group 
differences of the second scan. In the second scan, (a) we found significant differences 
between the APOE e4 non-carriers (e3/e3) and carriers (e3/e4 and e4/e4) overall at the 
left hippocampus (p =0.0086), but not in right part (p =0.5489). (b) Similar only left 
hippocampal significant differences held between the APOE e4 non-carriers (e3/e3) and 
the APOE e4 heterozygotes (e3/e4) (p = 0.0165), (c) and between the APOE e4 non-
carriers (e3/e3) and the APOE e4 homozygotes (e4/e4) of the left part of hippocampus (p 
=0.0192) but not in right side (p = 0.4778, p = 0.0916 for heterozygotes and homozygotes 
respectively compared to non-carriers).  
 
Figure 10. Illustration of local shape differences (P values) of BAI second scan. 
 
3.4 Cumulative Distribution Functions of the p-values in the Statistical p-maps  
 In Figure 11, we organized some cumulative distribution functions (CDF) of the 
p-values observed in four group difference experiments in the full ADNI cohort. 
Specifically, we chose those experimental results that passed the permutation based 
multiple comparison tests (i.e., after correcting for multiple comparisons, p<0.05). Since 
there are too few homozygote samples in the 24-moth follow up cohort (56 subjects in 
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the full ADNI cohort), we also excluded the CDF from the 24-month follow up cohort. 
The CDFs of p-values are plotted against the corresponding p-value that would be 
expected, under the null hypothesis of no group difference, for all above experiments 
shown in Figures 11. For null distributions, the cumulative distribution of p-values is 
expected to fall approximately along the dotted line. Large deviations from that curve are 
associated with significant signal, and greater effect sizes represented by larger deviations. 
The theory of false discovery rates (FDR) (Benjamini and Hochberg, 1995) gives 
formulae for thresholds that tend to control false positives at a known rate. This protocol 
was adopted in several of our prior papers (Shi et al., 2014; Shi et al., 2013a; Shi et al., 
2013q; Wang et al., 2015b; Wang et al., 2011; Wang et al., 2013; Wang et al., 2010) as 
an empirical standard to compare effects in group difference analysis. We note that the 
deviation of the statistics from the null distribution generally increases longitudinally 
from 6-month, to 12-month and 24 month data in the full ADNI cohort. It shows that the 
continually accelerated atrophy between APOE e4 carriers and non-carriers (Figure 11 
(a)), APOE e4 heterozygotes and homozygotes (Figure 11 (b)) and APOE e4 










Figure 11. Cumulative Distribution Function (CDF) plots comparison. 
Following our prior work (Shi et al., 2014), we drew some CDFs of the p-values 
observed in group difference between e4 homozygotes and non-carriers and e4 
heterozygotes and non-carriers in the full ADNI cohort as shown in Figure 12. From the 
CDF plots, we can observe the trend that all follow up cohorts, APOE e4 homozygotes 
appear to differ more from non-carriers than do e4 heterozygotes, so does the results from 
6-month follow up cohort. Such a simple empirical comparison may suggest a clear 






Figure 12. Cumulative Distribution Function (CDF) plots comparisons on the 
group differences   between APOE e4 homozygotes and non-carriers, APOE e4 
heterozygotes and non-carriers. The results demonstrate the APOE e4 dose effect on 











In our current work, with the full ADNI cohort, we found statistical significance 
between e4 carriers and non-carriers on all three follow up cohorts (Figure 2), e4 
homozygotes and heterozygotes on 6- and 12-month follow up cohorts but not on 24-
month follow up cohort (Figure 4), e4 homozygotes and non-carriers on all three follow 
up cohorts (Figure 6), e4 heterozygotes and non-carriers on all three follow up cohorts 
(Figure 8). Also, from the CDF shown in Figure 11, we can observe the trend that the 
group differences roughly appear to be sharper as time goes, except two group 
differences involving e4 homozygotes on the 24-month cohort. Our results are consistent 
with our observations on the baseline cohort (Shi et al., 2014) and another prior work 
(Pievani et al., 2011) in a relatively small dataset (, suggesting a clear relationship 
between APOE genotype and hippocampal atrophy in full ADNI cohort at all four time 
points. On the other hand, some prior work (e.g. (Crivello et al., 2010; Lemaitre et al., 
2005; Lyall et al., 2013; Protas et al., 2013; Soininen et al., 1995)) reported no APOE e4 
gene dose effect on hippocampal atrophy. In a relatively large imaging cohort (N=1925), 
we found that in the full ADNI cohort, the APOE e4 dose is associated with greater 
hippocampal deformation (Figure 12). Although more rigorous statistical tests are 
certainly necessary, from the p-maps and CDF plots, we can observe the trend that in 
these groups shown in Figure 12, APOE e4 homozygotes appear to differ more from 
non-carriers than do e4 heterozygotes. Our findings confirm and extend our observation 
that the APOE e4 dose is associated with great hippocampal deformation, and they 
support that sMRI hippocampal morphometry measure may become a valid imaging 
biomarkers to track AD progression and intervention. 
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Consistent with our prior study on non-demented ADNI cohort (Shi et al., 2014), 
our studied detected significant difference in most of group differences on non-demented 
ADNI cohorts, except for homozygotes vs. heterozygotes on 6- and 24-month follow up 
cohorts, heterozygotes and non-carriers on 12-month follow up cohort and homozygotes 
and non-carriers on 24-month follow up cohorts. However, the effects of homozygotes on 
regional patterns of hippocampal morphometry at 24-month follow up did not pass the 
permutation tests when comparing with heterozygotes or non-carriers, probably as a 
results of insufficient statistical power, as sample sizes were much smaller (N=35) only 
than other subjects numbers. We found significant differences between e4 homozygotes 
and heterozygotes on 12-month follow up non-demented cohorts, e4 homozygotes and 
non-carriers on the 6- and 12-month follow up non-demented cohorts. Note that, in our 
prior work (Shi et al., 2014), we did not detect difference between homozygotes and 
heterozygotes on the baseline non-demented cohort. Here we detected increasing 
difference comparing homozygotes with heterozygotes on 12-month follow up non-
demented cohort, homozygotes and non-carriers on both 6- and 12-month follow up non-
demented cohorts. It supports our hypothesis that the homozygotes may have an 
accelerated atrophy comparing with two other groups and there exists an association 
between APOE does and hippocampal deformation for non-demented population. The 
fact that we detected statistical difference between heterozygotes and non-carriers on 
both baseline and 6-month follow up non-demented cohort while not in 12-month follow 
up non-demented cohort, may suggest that the decreasing of hippocampal volume is also 
associated with normal aging. However, for a complete understanding of the longitudinal 
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APOE dose effect on non-demented population, we still need more systematic validation 
and comparison studies.  
Prior work (Cohen et al., 2001; Farrer et al., 1997; Lemaitre et al., 2005; O'Dwyer 
et al., 2012) found greater differences on the right hippocampus when comparing 
heterozygotes and homozygotes APOE e4 groups with non-carriers. In contrast, our 
results suggest carriers, heterozygotes and homozygotes APOE e4 patients have greater 
deformities for the left than the right hippocampus when comparing with non-carriers. By 
contrast with comparisons of APOE e4 carriers vs. non-carriers, differences between the 
heterozygotes and homozygotes APOE e4 groups were greater on the right side than on 
the left. Our results are consistent with some prior work (Morra et al., 2009c; Pievani et 
al., 2011; Shi et al., 2014). They may suggest that the APOE e4 dose effects start from 
the left side and further extend to the right side when considering people at 3 levels of 
genetic risk for AD by carrying 0, 1, or 2 copies of the APOE e4 allele. 
To our knowledge, it is the first study to apply a surface-based approach to study 
the longitudinal APOE e4 gene dose effects on hippocampal morphometry differences 
among subjects with different genetic risk levels for late-onset AD. Prior work (Morra et 
al., 2009c; Qiu et al., 2009; Roussotte et al., 2014a; Roussotte et al., 2014e; Shi et al., 
2014) has demonstrated that surface based subregional structure analysis may offer 
additional benefits, such as better visualization and increased statistical power, for 
genetic influence analysis.  
There is an ever growing variety of methods for examining the structure and 
function of the hippocampus via in vivo MR images (de Flores et al., 2015; Hao et al., 
2014). Extensive studies have focused on examining the subfields of the hippocampal 
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formation and subregions of the parahippocampal gyrus (Van Leemput et al., 2009; 
Wang et al., 2006; Wang et al., 2003; Yassa et al., 2010; Yushkevich et al., 2015a; 
Yushkevich et al., 2015b), which segment hippocampus into different regions and 
analyze the volume and shape changes of these subfields. These methods compute 
volumetric image registration between template and individual subject and translate and 
visualize the deformation on surfaces. Surface-based hippocampal shape analyses rely 
primarily on two components. First, to build an appropriate representation and 
correspondence between hippocampal shapes. Second, to carry out group analysis based 
within this common domain. Surface parameterization methods (Brechbühler et al., 1995; 
Gu et al., 2004; Wang et al., 2007c) play an important role to build a canonical space to 
match hippocampal surfaces. When the canonical space is a sphere, the spherical 
harmonic functions (SPHARM) based approaches (Gutman et al., 2009; Shen et al., 2009; 
Styner et al., 2004) use the coefficients of the harmonic expansion to infer shape 
differences between patient groups and controls. Another group of methods is aimed to 
build dense correspondence between surfaces (Csernansky et al., 2000; Wang et al., 
2007a; Wang et al., 2011). For example, the Large Deformation Diffeomorphic Metric 
Mapping (LDDMM) (Joshi and Miller, 2000) has been used to deform labeled 
anatomical templates of the hippocampus onto new images, using a combination of 
manual land marking of points on the hippocampus and 3D fluid image registration 
(Csernansky et al., 2000; Haller et al., 1996; Wang et al., 2007a). Other dense mapping 
methods registered hippocampal surfaces with surface geometric features (Apostolova et 
al., 2010; Cho et al., 2011; Morra et al., 2009a; Qiu et al., 2009; Shi et al., 2013a; 
Thompson et al., 2004). For group difference analysis, while some work used single low 
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dimensional feature vector (Kim et al., 2012a; Wachinger et al., 2015; Yang et al., 2013), 
other detailed local geometric features such as medial distance (Thompson et al., 2004), 
the LDDMM metric (Younes et al., 2014), and tensor-based morphometry (Wang et al., 
2011) were also widely adopted for detailed statistical shape analysis. This type of 
methods affords the benefits of high resolution information from the hippocampal surface 
representation and efficient numerical solutions to register and analyze surface 
deformation across subjects.  
Another important way studying APOE e4 dose effect is to investigate the 
correlation between number of APOE e4 alleles and multivariate statistics using linear 
discriminant analysis-based model (Chen et al., 2007; Roussotte et al., 2014a), depicting 
relationships between number of APOE e4 alleles (0, 1 or 2) and multivariate statistics of 
the left hippocampal surfaces. With normal group mean as the average, we first converted 
our multivariate statistics to a univariate index with the Mahalanobis distance. We 
applied a linear regression to study the correlation where the number of APOE e4 alleles 
as the predictor and the difference between the follow up and the baseline of the 
univariate index data as the outcome variable. Our experiment showed that carrying more 
APOE e4 alleles was associated with hippocampal surface atrophy, and this association 
was more widespread and more significant at 24-month than at 6-month (but not at 12-
month). In Figure 13 (a), (b), blue to red hues indicate regions where higher APOE e4 
loading is associated with atrophy of the surfaces, after controlling for age and sex. We 
also studied this linear correlation in the non-demented ADNI cohort. After controlling 
for age and sex, none of the experiments on these three follow up time points passed the 
FDR correction. It does not necessarily suggest that higher APOE e4 load is not 
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associated with hippocampal atrophy effect, as we discovered from our group difference 
studies. In a threshold statistical map, the power can be insufficient to detect the presence 
of APOE e4 dose effects if present. Prior work (Roussotte et al., 2014a) reported that 
surface-based patterns of ventricular expansion in dementia and normal aging in the full 
ADNI cohort. It may be due to that the effect sizes of APOE genotype on ventricular 
enlargement were much lager than those on hippocampal atrophy. Even so, our findings 
are consistent with our baseline result (Shi et al., 2014) and demonstrate the APOE dose 
effect trend on hippocampal atrophy. The results may mean that this relatively large 
sample was limited in statistical power that cannot be detected with our current software 
assuming such effects exist. Our continuing work on geometric shape analysis (e.g. (Mi 
et al., 2015; Shi et al., 2015) may provide new insights to this study in future. 
 
Figure 13. Linear Correlation 
Between number of APOE e4 




As noted in Shi, et al. (2014), there are two main caveats in our current work. First, 
the ADNI participants are generally elderly, they may not be the best representative of 
patient populations in clinical trials. Our ongoing study on the association of APOE e4 
genotype and hippocampal morphometry (Li et al., 2015) on a cognitively normal cohort, 
Arizona APOE cohort (Caselli et al., 2009), represents our latest efforts to corroborate 
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and extend our current biological discoveries to younger and healthy population. Even so, 
our current findings may support the genetic influence of APOE genotype on non-
demented cohort. Second, we excluded the APOE e2 carriers from our current study 
because of the extremely low number of APOE e2 carriers in ADNI dataset.  
Even so, we were able to show that with our novel hippocampal morphometry 
system in the longitudinal ADNI datasets, we replicated the influence of APOE genotype 
on hippocampal morphometry observed in the baseline study (Shi et al., 2014). We also 
demonstrated the strong dose effects of APOE genotype on the 6-month and 12-month 
follow up cohorts. Our work may provide practical experience for further investigation 
on human hippocampus surface in AD research.  
In future, we will continue developing novel imaging shape analysis systems to 
increase the sensitivity on genetic influence detection and further on AD prognosis and 
prevention. We plan to apply this framework together with our ventricular morphometry 
system (Wang et al., 2011) and cortical thickness estimation system (Wang et al., 2015a) 
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